A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the SHOCK Trial and Registry.
BACKGROUND
Early revascularization (ERV) is beneficial in the management of cardiogenic shock (CS) complicating myocardial infarction. The severity of CS varies widely, and identification of independent risk factors for outcome is needed. The effect of ERV on mortality in different risk strata is also unknown. We created a severity scoring system for CS and used it to examine the potential benefit of ERV in different risk strata using data from the SHOCK Trial and Registry.


METHODS
Data from 1,217 patients (294 from the randomized trial and 923 from the registry) with CS due to pump failure were included in a Stage 1 severity scoring system using clinical variables. A Stage 2 scoring system was developed using data from 872 patients who had invasive hemodynamic measurements. The outcome was in-hospital mortality at 30 days.


RESULTS
In-hospital mortality at 30 days was 57%. Multivariable modeling identified 8 risk factors (Stage 1): age, shock on admission, clinical evidence of end-organ hypoperfusion, anoxic brain damage, systolic blood pressure, prior coronary artery bypass grafting, noninferior myocardial infarction, and creatinine > or = 1.9 mg/dL (c-statistic = 0.74). Mortality ranged from 22% to 88% by score category. The ERV benefit was greatest in moderate- to high-risk patients (P = .02). The Stage 2 model based on patients with pulmonary artery catheterization included age, end-organ hypoperfusion, anoxic brain damage, stroke work, and left ventricular ejection fraction <28% (c-statistic = 0.76). In this cohort, the effect of ERV did not vary by risk stratum.


CONCLUSIONS
Simple clinical predictors provide good discrimination of mortality risk in CS complicating myocardial infarction. Early revascularization is associated with improved survival across a broad range of risk strata.
Sleeper
Lynn A
LA
New England Research Institutes, Watertown, MA 02472, USA. lsleeper@neriscience.com
Reynolds
Harmony R
HR
White
Harvey D
HD
Webb
John G
JG
Dzavík
Vladimir
V
Hochman
Judith S
JS
D000368:Aged; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D016015:Logistic Models; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000601:surgery; D009204:Myocardial Revascularization; D012042:Registries; D018570:Risk Assessment; D012720:Severity of Illness Index; D012770:Shock, Cardiogenic / Q000209:etiology / Q000401:mortality*
Eur Heart J. 2005 Jul;26(13):1276-83
15734771
Am Heart J. 1999 Jul;138(1 Pt 1):21-31
10385759
Heart. 2007 Feb;93(2):177-82
16757543
Am Heart J. 2004 Feb;147(2):253-9
14760322
J Thromb Thrombolysis. 2005 Feb;19(1):33-9
15976965
N Engl J Med. 1999 Apr 15;340(15):1162-8
10202167
Eur Heart J. 2003 Feb;24(3):258-65
12590903
Am Heart J. 1999 Feb;137(2):313-21
9924166
Am J Cardiol. 2005 Jul 1;96(1):35-41
15979429
Arch Intern Med. 2005 Jan 10;165(1):83-7
15642879
Am Heart J. 1967 Oct;74(4):578-81
6047781
Heart. 2005 Mar;91(3):339-44
15710715
Am J Cardiol. 2002 Oct 15;90(8):838-42
12372570
J Am Coll Cardiol. 2004 Jul 21;44(2):340-8
15261929
N Engl J Med. 1999 Aug 26;341(9):625-34
10460813
JAMA. 2006 Jun 7;295(21):2511-5
16757723
Am Heart J. 2005 Jan;149(1):98-103
15660040
JAMA. 2005 Jul 27;294(4):448-54
16046651
Circulation. 1997 Jul 1;96(1):122-7
9236426
Eur Heart J. 2004 Feb;25(4):322-8
14984921
Am Heart J. 2008 Feb;155(2):267-73
18215596